Divestment of radiopharmaceutical business of CIS bio international completed

09-May-2006

The Schering AG Group announced that its French subsidiary Schering S.A.S. has completed the transfer of the radiopharmaceutical business of CIS bio international to a consortium formed by the Belgian companies Ion Beam Applications S.A. (IBA) and the Institut National des Radioéléments (IRE). The respective agreement was signed on February 22, 2006.

As part of the transaction, the consortium has acquired Schering's current radiopharmaceutical business while Schering continues to focus on the promising innovative diagnostic fields of Magnetic Resonance Imaging, Computer Tomography and optical as well as molecular imaging.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances